Literature DB >> 12753669

Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease.

E Bolognesi1, K Karell, S Percopo, I Coto, L Greco, V Mantovani, E Suoraniemi, J Partanen, K Mustalahti, M Mäki, P Momigliano-Richiardi.   

Abstract

Although HLA-DQ genes are the major celiac disease (CD) susceptibility genes, results from Finnish families suggest that not all DQ2-encoding haplotypes confer equal susceptibility to CD, implying the effect of other gene(s) in the HLA region. The aim of the present work was to extend and confirm the aforementioned results in a southern European population ( Italian) and to better localize the additional risk factor/s. The association of nine loci spanning the HLA region from DR to HFE, 4.5-Mb telomeric of HLA-A, was tested. The analysis was performed by comparing marker frequencies in DR3-DQ2 haplotypes transmitted and non-transmitted to the affected offspring in 156 Italian CD families selected for having at least one DR3-positive parent. The same analysis was performed independently in 101 Finnish CD families selected with the same criteria. Three alleles, MICA-A5.1, MICB-CA24 and MIB-350, all characteristic of the B8-DR3 extended haplotype, showed a significantly increased frequency in DR3 transmitted haplotypes in the Italian families. DR3 haplotypes carrying the combination of these alleles conferred an approximate fourfold increased CD risk. B8-DR3 transmitted haplotypes were significantly more conserved telomerically down to the MIC-Class I region. Similar results were seen in the Finnish families. The major conclusion that holds true in both populations is that, while DQ2 is an absolute requirement for the development of CD, the presence of an additional genetic factor within the MIC-Class I region confers an approximate 4-fold increased risk of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753669     DOI: 10.1034/j.1399-0039.2003.00028.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  6 in total

Review 1.  The roles of MHC class II genes and post-translational modification in celiac disease.

Authors:  Ludvig M Sollid
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 2.846

2.  Evidence of a correlation between mannose binding lectin and celiac disease: a model for other autoimmune diseases.

Authors:  Michele Boniotto; Laura Braida; Valentina Baldas; Tarcisio Not; Alessandro Ventura; Serena Vatta; Oriano Radillo; Francesco Tedesco; Selvaggia Percopo; Marcella Montico; Antonio Amoroso; Sergio Crovella
Journal:  J Mol Med (Berl)       Date:  2005-01-06       Impact factor: 4.599

3.  HLA genotyping in pediatric celiac disease patients.

Authors:  Biljana Stanković; Nedeljko Radlović; Zoran Leković; Dragana Ristić; Vladimir Radlović; Gordana Nikčević; Nikola Kotur; Ksenija Vučićević; Tatjana Kostić; Sonja Pavlović; Branka Zukic
Journal:  Bosn J Basic Med Sci       Date:  2014-08-16       Impact factor: 3.363

4.  A functional variant in ERAP1 predisposes to multiple sclerosis.

Authors:  Franca Rosa Guerini; Rachele Cagliani; Diego Forni; Cristina Agliardi; Domenico Caputo; Andrea Cassinotti; Daniela Galimberti; Chiara Fenoglio; Mara Biasin; Rosanna Asselta; Elio Scarpini; Giacomo P Comi; Nereo Bresolin; Mario Clerici; Manuela Sironi
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

5.  HLA-class I markers and multiple sclerosis susceptibility in the Italian population.

Authors:  L Bergamaschi; M A Leone; M E Fasano; F R Guerini; D Ferrante; E Bolognesi; N Barizzone; L Corrado; P Naldi; C Agliardi; E Dametto; M Salvetti; A Visconti; D Galimberti; E Scarpini; M Vercellino; R Bergamaschi; F Monaco; D Caputo; P Momigliano-Richiardi; S D'Alfonso
Journal:  Genes Immun       Date:  2009-11-12       Impact factor: 2.676

6.  HLA and celiac disease susceptibility: new genetic factors bring open questions about the HLA influence and gene-dosage effects.

Authors:  Luz María Medrano; Bárbara Dema; Arturo López-Larios; Carlos Maluenda; Andrés Bodas; Natalia López-Palacios; M Ángeles Figueredo; Miguel Fernández-Arquero; Concepción Núñez
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.